HDAC9 and cancer: Among the various substances that can target HATs/HDACs directly, or those associated with molecules in acetylation/deacetylation-relevant signaling pathways, HDAC inhibitors have become a large focus of research and been applied with various degrees of success in different settings to treat cancer (139).